Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen

Therapeutic Drug Monitoring

Volumn 31, Issue 1, 2009, Pages 95-103

  Ekhart, Corine ^a,d   Rodenhuis, Sjoerd ^b   Beijnen, Jos H ^a,c   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Cyclophosphamide; Population pharmacokinetics; Therapeutic drug monitoring; Thiotepa

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CARBOPLATIN; CYCLOPHOSPHAMIDE; DRUG METABOLITE; TEPA; THIOTEPA;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG MEGADOSE; DRUG POTENTIATION; FEMALE; GAS CHROMATOGRAPHY; GERM CELL TUMOR; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; OVARY CANCER; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOTRANSFORMATION; BREAST NEOPLASMS; CHROMATOGRAPHY, GAS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOPHOSPHAMIDE; EXPECTORANTS; FEMALE; FORECASTING; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESNA; MODELS, STATISTICAL; NEOPLASMS, GERM CELL AND EMBRYONAL; OVARIAN NEOPLASMS; TESTICULAR NEOPLASMS; THIOTEPA;

EID: 60449110986     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e318194e484     Document Type: Article

References (33)

1. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16.
2. Rodenhuis S, Bontenbal M, van Hoesel QG, et al. Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol. 2006;17:588-596.
3. Stemmer SM, Hardan I, Brenner HJ, et al. High-dose chemotherapy and autologous stem cell transplant in women with de novo chemosensitive metastatic breast cancer. Am J Clin Oncol. 2004;27:250-255.
4. de Jonge ME, Huitema ADR, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44:1135-1164.
5. Przepiorka D, Madden T, Ippoliti C, et al. Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol. 1995;37:155-160.
6. Busse D, Busch FW, Bohnenstengel F, et al. Dose escalation of cyclophosphamide in patients with breast cancer: consequences for pharmacokinetics and metabolism. J Clin Oncol. 1997;15:1885-1896.
7. Huitema ADR, Kerbusch T, Tibben MM, et al. Reduction of cyclophosphamide bioactivation by thiotepa: critical sequence-dependency in high-dose chemotherapy regimens. Cancer Chemother Pharmacol. 2000;46:119-127.
8. de Jonge ME, Huitema ADR, Rodenhuis S, et al. Integrated population pharmacokinetic model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction. J Pharmacokinet Pharmacodyn. 2004;31:135-156.
9. Huitema ADR, Smits KD, Mathot RA, et al. The clinical pharmacology of alkylating agents in high-dose chemotherapy. Anticancer Drugs. 2000;11: 515-533.
10. Schrama JG, Baars JW, Holtkamp MJ, et al. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer. Bone Marrow Transplant. 2001;28:173-180.
11. Westermann AM, Holtkamp MM, Linthorst GA, et al. At home management of aplastic phase following high-dose chemotherapy with stem-cell rescue for hematological and non-hematological malignancies. Ann Oncol. 1999;10:511-517.
12. Schrama JG, Holtkamp MJ, Baars JW, et al. Toxicity of the high-dose chemotherapy CTC regimen (cyclophosphamide, thiotepa, carboplatin): The Netherlands Cancer Institute experience. Br J Cancer. 2003;88: 1831-1838.
13. Rodenhuis S, Richel DJ, van der WE, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998; 352:515-521.
14. Rodenhuis S, Westermann A, Holtkamp MJ, et al. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer. J Clin Oncol. 1996;14:1473-1483.
15. Rodenhuis S, de Wit R, de Mulder PH, et al. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission. Ann Oncol. 1999;10:1467-1473.
16. Ekhart C, Gebretensae A, Rosing H, et al. Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci. 2007;854:345-349.
17. Huitema ADR, Tibben MM, Kerbusch T, et al. Simultaneous determination of N, N′, Nu″-triethylenethiophosphoramide, cyclophospha-mide and some of their metabolites in plasma using capillary gas chromatography. J Chromatogr B Biomed Sci Appl. 1998;716:177-186.
18. Jonsson EN, Karlsson MO. Xpose - an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64.
19. Hussein AM, Petras WP, Ross M, et al. A phase I/II study of high-dose cyclophosphamide, cisplatin, and thioTEPA followed by autologous bone marrow and granulocyte colony-stimulating factor-primed peripheral-blood progenitor cells in patients with advanced malignancies. Cancer Chemother Pharmacol. 1996;37:561-568.
20. O'Dwyer PJ, LaCreta F, Engstrom PF, et al. Phase I/pharmacokinetic reevaluation of thioTEPA. Cancer Res. 1991;51:3171-3176.
21. Heideman RL, Cole DE, Balis F, et al. Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. Cancer Res. 1989;49:736-741.
22. Henner WD, Shea TC, Furlong EA, et al. Pharmacokinetics of continuous-infusion high-dose thiotepa. Cancer Treat Rep. 1987;71: 1043-1047.
23. Ackland SP, Choi KE, Ratain MJ, et al. Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide. J Clin Oncol. 1988;6:1192-1196.
24. Hagen B. Pharmacokinetics of thio-TEPA and TEPA in the conventional dose-range and its correlation to myelosuppressive effects. Cancer Chemother Pharmacol. 1991;27:373-378.
25. Lazarus HM, Reed MD, Spitzer TR, et al. High-dose i.v. thiotepa and cryopreserved autologous bone marrow transplantation for therapy of refractory cancer. Cancer Treat Rep. 1987;71:689-695.
26. Bagley CM Jr, Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 1973;33:226-233.
27. Wilkinson PM, O'Neill PA, Thatcher N, et al. Pharmacokinetics of high-dose cyclophosphamide in patients with metastatic bronchogenic carcinoma. Cancer Chemother Pharmacol. 1983;11:196-199.
28. Mouridsen HT, Faber O, Skovsted L. The metabolism of cyclophosphamide. Dose dependency and the effect of long-term treatment with cyclophosphamide. Cancer. 1976;37:665-670.
29. Brock N, Gross R, Hohorst HJ, et al. Activation of cyclophosphamide in man and animals. Cancer. 1971;27:1512-1529.
30. Milsted RA, Jarman M. Metabolism of high doses of cyclophosphamide. Cancer Chemother Pharmacol. 1982;8:311-313.
31. Chen TL, Passos-Coelho JL, Noe DA, et al. Nonlinear pharmacokinetics of cyclophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Cancer Res. 1995;55:810-816.
32. Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophospharmde/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation. Drug Metab Dispos. 1997;25:544-551.
33. Yule SM, Boddy Ay Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J Clin Pharmacol. 1996;41:13-19.